On March 19, 2026, Seattle-based biopharmaceutical firm Atossa Therapeutics officially announced the addition of two key figures to its clinical... Read more
Tag: #Global Trends
Novartis agrees to $3B acquisition of mutant-selective breast cancer therapy
On March 20, 2026, Novartis announced an agreement with Synnovation Therapeutics to acquire Pikavation Therapeutics, the subsidiary holding the SNV4818... Read more
Roche halts experimental SMA drug development following inconsistent trial results
On March 20, 2026, Swiss pharmaceutical giant Roche officially announced the discontinuation of emugrobart, an experimental antibody aimed at treating... Read more
Earendil Labs hauls in $787M to advance AI-powered biologics
On March 20, 2026, Earendil Labs—a biotechnology startup with operations in both the U.S. and China—announced the successful closing of... Read more
Wave of affordable generics hits India as Semaglutide patents expire
March 20, 2026, marks a pivotal milestone for the Indian pharmaceutical industry as patents for Semaglutide (the active ingredient in... Read more
Indian generics set to reshape the global weight-loss drug market
The upcoming patent expiry of semaglutide on March 20 in India is paving the way for a surge in affordable... Read more
Argentina officially concludes withdrawal from World Health Organization
The Argentine government has confirmed the termination of its membership in the World Health Organization (WHO). This move signifies a... Read more
SK pharmteco’s U.S. facility successfully clears FDA regulatory inspection
SK pharmteco has announced the successful completion of a regulatory inspection conducted by the U.S. Food and Drug Administration (FDA)... Read more
Green Elephant Biotech unveils Archimedes One to streamline cell therapy manufacturing
Green Elephant Biotech has introduced Archimedes One, the pioneer in a new category of "Dynamic Adherent Bioreactors." The system is... Read more









